Heidi Cuthbert

Aged care giant Regis Healthcare (ASX:REG) reported a sharp 45.1% decline in statutory net profit for the first half of FY26, falling to $13.4 million.

Three days after the Supreme Court torpedoed most of Donald Trump’s global tariffs, markets are still cheering the rollback of his 10% import wall and the curb on presidential emergency powers.

Bayer has filed a lawsuit against Johnson & Johnson (NYSE:JNJ) and its subsidiary Janssen Biotech, alleging the healthcare giant is using "scientifically flawed" and misleading marketing to steal market share for its prostate cancer treatment, Erleada.

Gossamer Bio (NASDAQ:GOSS) announced topline results from its pivotal PROSERA Phase 3 Study on Monday, February 23, 2026.

Axsome Therapeutics (NASDAQ:AXSM) reported a surge in full-year 2025 revenue on Monday, fueled by the rapid commercial scaling of its depression and sleep disorder treatments.

Merck & Co. (NYSE: MRK), known as MSD outside the U.S. and Canada, announced a significant restructuring of its Human Health division on Monday, February 23, 2026.

Gilead Sciences (NASDAQ:GILD) announced Monday it has entered into a definitive agreement to acquire Arcellx (NASDAQ:ACLX), moving to take full control of a high-potential cell therapy pipeline for multiple myeloma.

Grayscale said XRP is among the most discussed digital assets after bitcoin in conversations between financial advisors and their clients.

Pro-Ripple lawyer and US Senate candidate John Deaton has rejected calls to pardon former FTX chief executive Sam Bankman-Fried, dismissing recent claims that the exchange was solvent before its 2022 collapse.

Investor capital is rotating from newly launched crypto tokens into publicly listed crypto companies as more than 80% of 2025 token launches trade below their token generation event price, according to DWF Labs.